Completed PHASE1 INTERVENTIONAL 1-arm NCT01438944

Evaluation of Transdermal Nicotine Replacement Therapy (NRT) Activity Through Metabolic Induction

Evaluation of Nicotine Receptor Up-regulation Activity Through Metabolic Induction and Changes in Responsiveness Using Surrogate Evaluation Methods

Sponsor: Basil Hetzel Institute for Translational Research

Conditions Addiction Smoking

Interventions Nicabate 21mg transdermal NRT

Updated 7 times since 2017 Last updated: Apr 7, 2017 Started: Jul 31, 2011 Primary completion: Jul 31, 2015 Completion: Sep 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Addiction and Smoking and is currently completed. Basil Hetzel Institute for Translational Research leads this study, which shows 7 recorded versions since 2011 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
May 2017 — Jun 2018 [monthly]

Completed PHASE1

Status: Unknown Status → Completed

▶ Show 2 earlier versions

Feb 2017 — May 2017 [monthly]

Unknown Status PHASE1
Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE1

First recorded

Jul 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Basil Hetzel Institute for Translational Research
Clinical Practice Unit
The Queen Elizabeth Hospital
Therapeutics Research Centre
University of Adelaide
University of South Australia

Data source: The Queen Elizabeth Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Adelaide, Australia